Lakefront Biotherapeutics NV 2018 SR
The report details Galapagos' commitment to improving healthcare through the discovery of breakthrough therapies for inflammation and fibrosis. In 2018, the company successfully nominated four new preclinical candidates and initiated a Phase 3 clinical program. The workforce grew by 21% to 725 employees, with women representing 33% of senior management and approximately 43% of the board of directors. The company also established an EHS framework based on ISO 14001 and ISO 45001 standards, reporting zero workplace fatalities or safety incidents during the year.
Company: Lakefront Biotherapeutics NV
Sector: Professional & technical services
Country: Belgium
Year: 2018
Type: SR
Pages: 12
Back to company
Lakefront Biotherapeutics NV
CSR Report
The report details Galapagos' commitment to improving healthcare through the discovery of breakthrough therapies for inflammation and fibrosis. In 2018, the company successfully nominated four new preclinical candidates and initiated a Phase 3 clinical program. The workforce grew by 21% to 725 employees, with women representing 33% of senior management and approximately 43% of the board of directors. The company also established an EHS framework based on ISO 14001 and ISO 45001 standards, reporting zero workplace fatalities or safety incidents during the year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees